TY - JOUR
T1 - Quantification of [18F]florbetaben amyloid-PET imaging in a mixed memory clinic population
T2 - The ABIDE project
AU - Collij, Lyduine E.
AU - Salvadó, Gemma
AU - de Wilde, Arno
AU - Altomare, Daniele
AU - Shekari, Mahnaz
AU - Gispert, Juan Domingo
AU - Bullich, Santiago
AU - Stephens, Andrew
AU - Barkhof, Frederik
AU - Scheltens, Philip
AU - Bouwman, Femke
AU - van der Flier, Wiesje M.
N1 - Funding Information: Research of the Alzheimer Centre Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Centre Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. WMvdF holds the Pasman chair. WMvdF is recipient of the collaboration project ABIDE‐clinical utility, which is co‐funded by the PPP Allowance made available by health‐Holland, Top Sector Life Sciences & Health, to stimulate public‐private partnerships and Life Molecular Imaging GmbH (grant no. LSHM18075). WMvdF is recipient of ABOARD, which is a public‐private partnership receiving funding from ZonMW (#73305095007), Alzheimer Nederland and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). More than 30 partners contribute to ABOARD. ABIDE has been funded in the context of the Dutch national dementia plan (project number: 733050201). The project leading to this article has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors and neither the IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - Introduction: We investigated amyloid-burden quantification in a mixed memory clinic population. Methods: [18F]Florbetaben amyloid-PET (positron emission tomography) scans of 348 patients were visually read and quantified using the Centiloid (CL) method. General linear models were used to assess CL differences across syndromic and etiological diagnosis. Linear mixed models were fitted to assess the predictive value of visual read (VR) and CL on longitudinal Mini-Mental Status Examination (MMSE). Results: CL was associated with syndromic (F = 4.42, p = 0.014) and etiological diagnosis (F = -12.66, p < 0.001), with Alzheimer's disease (AD) patients showing the highest amyloid burden (62.9 ± 27.5), followed by dementia with Lewy bodies (DLB) (25.3 ± 35.5) and cardiovascular disease (CVD) (16.7 ± 24.5), and finally frontotemporal lobe degeneration (FTLD) (5.0 ± 17.22, t = –12.66, p < 0.001). CL remained predictive of etiological diagnosis (t = –2.41, p = 0.017) within the VR+ population (N = 157). VR was not a significant predictor of MMSE (t = –1.53, p = 0.13) for the SCD population (N = 90), whereas CL was (t = -3.30, p = 0.001). Discussion: The extent of amyloid pathology through quantification holds clinical value, potentially in the context of differential diagnosis as well as prognosis.
AB - Introduction: We investigated amyloid-burden quantification in a mixed memory clinic population. Methods: [18F]Florbetaben amyloid-PET (positron emission tomography) scans of 348 patients were visually read and quantified using the Centiloid (CL) method. General linear models were used to assess CL differences across syndromic and etiological diagnosis. Linear mixed models were fitted to assess the predictive value of visual read (VR) and CL on longitudinal Mini-Mental Status Examination (MMSE). Results: CL was associated with syndromic (F = 4.42, p = 0.014) and etiological diagnosis (F = -12.66, p < 0.001), with Alzheimer's disease (AD) patients showing the highest amyloid burden (62.9 ± 27.5), followed by dementia with Lewy bodies (DLB) (25.3 ± 35.5) and cardiovascular disease (CVD) (16.7 ± 24.5), and finally frontotemporal lobe degeneration (FTLD) (5.0 ± 17.22, t = –12.66, p < 0.001). CL remained predictive of etiological diagnosis (t = –2.41, p = 0.017) within the VR+ population (N = 157). VR was not a significant predictor of MMSE (t = –1.53, p = 0.13) for the SCD population (N = 90), whereas CL was (t = -3.30, p = 0.001). Discussion: The extent of amyloid pathology through quantification holds clinical value, potentially in the context of differential diagnosis as well as prognosis.
KW - Amyloid-PET
KW - Centiloid quantification
KW - Dementia
KW - Diagnosis
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85144070304&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/alz.12886
DO - https://doi.org/10.1002/alz.12886
M3 - Article
C2 - 36478646
SN - 1552-5260
JO - Alzheimer s & dementia
JF - Alzheimer s & dementia
ER -